deguelin has been researched along with Breast Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ann, J; Chen, J; Cho, TM; Choi, H; Chul Kim, K; Hoang, VH; Hong, M; Kim, HS; Kim, JY; Kim, KW; Lee, J; Lee, S; Nguyen, CT; Park, HJ; Seo, JH; Sub Byun, W; Suh, YG; Yong Kim, J | 1 |
| Ann, J; Byun, WS; Kim, JY; Kim, YJ; Lee, J; Lee, S; Nam, G; Nguyen, CT; Park, HJ; Park, S; Sahu, R; Seo, JH | 1 |
| Ann, J; Hong Seo, J; Kim, YJ; Lee, J; Min Park, J; Nam, G; Nguyen, CT; Park, HJ; Thanh La, M; Young Kim, J | 1 |
| Li, H; Wang, X; Wu, Z; Yi, T | 1 |
| Mehta, RG; Murillo, G; Peng, X; Torres, KE | 1 |
| Brown, PH; Rodenberg, JM | 1 |
| Chu, ZH; Huang, RF; Jiang, JW; Liang, XH; Zhan, Qz; Zhou, XL | 1 |
| Boo, HJ; Kim, JH; Kim, KW; Lee, HJ; Lee, HY; Lee, SH; Min, HY; Suh, YA; Suh, YG; Sung, MA; Yun, HJ | 1 |
| Karna, P; Lee, HY; Liu, X; Moriarty, RM; Naithani, R; O'Regan, RM; Peng, XH; Wood, WC; Yang, L | 1 |
| Casida, JE; Rowlands, JC | 1 |
10 other study(ies) available for deguelin and Breast Cancer
| Article | Year |
|---|---|
Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Models, Molecular; Molecular Structure; Rotenone; Structure-Activity Relationship | 2019 |
Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Molecular Docking Simulation; Rotenone; Structure-Activity Relationship | 2020 |
Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Molecular Docking Simulation; Molecular Structure; Rotenone; Structure-Activity Relationship | 2021 |
Enhancement radiosensitization of breast cancer cells by deguelin.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Rotenone; Survivin | 2008 |
Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Female; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rotenone; Signal Transduction; Tumor Cells, Cultured; Wnt Proteins | 2009 |
A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin.
Topics: beta Catenin; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Rotenone; Signal Transduction; Wnt Proteins | 2009 |
[Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway].
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rotenone; Signal Transduction | 2011 |
A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice; Mice, Nude; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Somatomedin; RNA Interference; Rotenone; Signal Transduction; Survivin; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Colony-Forming Units Assay; DNA Primers; Down-Regulation; Female; Genes, Reporter; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2007 |
NADH: ubiquinone oxidoreductase inhibitors block induction of ornithine decarboxylase activity in MCF-7 human breast cancer cells.
Topics: Breast Neoplasms; Electron Transport Complex I; Enzyme Induction; Epithelial Cells; Estradiol; Female; Humans; Insulin-Like Growth Factor I; NADH, NADPH Oxidoreductases; Ornithine Decarboxylase; Quinazolines; RNA, Messenger; Rotenone; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Uncoupling Agents | 1998 |